Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2019-12-09 Investor Presentation
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 9, 2019. It includes an investor presentation attached as Exhibit 99.1 for use at an update forum and references clinical data presentations. The document also reports a legal proceeding (lawsuit) against the company. The primary content is the investor presentation and related disclosures, not a full financial report or earnings release. The presence of an investor presentation as an exhibit and the nature of the filing indicate this is an Investor Presentation filing rather than an Annual Report, Earnings Release, or Legal Proceedings Report. Therefore, the most appropriate classification is Investor Presentation (IP).
2019-12-09 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-02 English
PRIMARY DOCUMENT
Director's Dealing
2019-12-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a press release announcing the completion of a rolling submission of a New Drug Application (NDA) to the FDA. The document is short (3850 characters) and primarily serves as an announcement of this event, including a press release as an exhibit. There are no financial statements or detailed financial data presented. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or capital update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-12-02 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a Regulation FD Disclosure about abstracts related to a therapeutic candidate to be presented at a conference. It also includes exhibits with abstracts but does not contain financial statements or detailed financial analysis. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing announcing specific information pursuant to SEC rules. The document length is 4561 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-11-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce major events. The text indicates it is a press release announcing FDA approval of a product, attached as an exhibit. There are no financial statements or detailed financial data present. The document is relatively short (3677 characters) and serves as a regulatory announcement rather than a full report. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings like 8-Ks that do not fit other categories.
2019-11-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.